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Abstract: As opposed to small molecules, macrocyclic peptides possess a large surface area and are
recognised as promising candidates to selectively treat diseases by disrupting specific protein–protein
interactions (PPIs). Due to the difficulty in predicting cyclopeptide conformations in solution, the de
novo design of bioactive cyclopeptides remains significantly challenging. In this study, we used the
combination of conformational analyses and molecular docking studies to design a new cyclopeptide
inhibitor of the interaction between the human tumour necrosis factor alpha (TNFα) and its receptor
TNFR-1. This interaction is a key in mediating the inflammatory response to tissue injury and
infection in humans, and it is also an important causative factor of rheumatoid arthritis, psoriasis and
inflammatory bowel disease. The solution state NMR structure of the cyclopeptide was determined,
which helped to deduce its mode of interaction with TNFα. TNFα sensor cells were used to evaluate
the biological activity of the peptide.
Keywords: cyclic peptides; NMR structure; drug design; protein–protein interaction
1. Introduction
Tumour necrosis factor alpha (TNFα) is a pleiotropic inflammatory cytokine produced and
secreted mainly by macrophages, which can also be produced by many other cells, for instance,
CD4+ lymphocytes, neutrophils, NK cells and mast cells [1]. TNFα plays an important role in the
pathogenesis of many chronic inflammatory diseases and its inhibition has been shown to be an effective
approach for therapy of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis
and inflammatory bowel disease [2]. The systemic inflammatory effects of TNFα are caused by its
soluble form, which exists as a homo-trimeric complex of 17-kDa subunits. It binds to two different
receptors: TNF Receptor-1 (TNFR-1), also known as [p55 (CD120a)], and TNF Receptor-2 (TNFR-2) [or
p75 (CD120b)], to which TNFα binds with relatively higher affinity compared to TNFR-1 [3].
Binding of either TNFR-1 or 2 to their ligand induces the receptor’s trimerisation. Both receptors
bind TNFα, with TNFR-1 being constitutively expressed in all cells, while TNFR-2 is inducibly
regulated mainly in haematopoietic and endothelial cells [4,5]. The TNFα-mediated clustering of
TNFR-1 initiates the signalling of pathways that lead to both apoptosis (through the caspase cascade)
and cell activation (through NF-kB) [6]. The NF-kB activation pathway following TNFα binding also
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induces pro-inflammatory cytokines like IL-4 and IL-8, responsible for the extensive tissue damage
seen in many chronic inflammatory diseases [7].
Small linear peptides (8–10 amino acids) are not appropriate as mimetics of the defined secondary
structures found in proteins, due to their intrinsic conformational flexibility. By contrast, the structural
rigidity of cyclic peptides makes them good mimetics of the protein conformational epitopes that lead
to interactions with proteins and ligands [8]. A common strategy to rigidify peptide structures is by
cyclisation, which could be via disulphide bridge formation or amide bond formation between N- and
C- termini. N- to C- cyclisation has the advantage that it usually leads to fewer rotatable bonds when
compared to disulphide bridge formation. Therefore, N- to C- cyclisation usually results in more rigid
and less flexible conformers [9].
A range of biologics targeting TNFα have been licensed for the treatment of various inflammatory
diseases, such as rheumatoid arthritis and Crohn’s disease [10]. Although these agents have high
potency and specificity, they are limited by their high production costs and potential immunogenicity.
For instance, large molecule biologics like infliximab have been associated with development of infusion
reaction (antigenicity) despite their high selectivity for TNFα [11]. Also, their large molecular weight
and low oral stability means their administration is only feasible through injection [12]. Several small
molecule synthetic inhibitors of TNFα are at different stages of pre-clinical and clinical development.
Thalidomide was the first to be developed and it inhibits TNFα production by promoting TNFα
mRNA degradation in stimulated monocytes [13]. This was followed by the discovery of other
classes of inhibitors targeting p38 MAP kinase, which controls TNFα production, TNFα converting
enzyme (TACE), and the mRNA coding for TNFα. The majority of these agents exhibited toxicities
related to their ability to cross the blood-brain barrier or by inhibition of liver cytochrome P450
enzyme [14]. Generally, the molecular size and lipophilicity of peptides determines their ability to cross
the physical and enzymatic barriers of the brain [15]. Peptide cyclisation as a means of overcoming these
two different types of barriers has only been successful with small opioid cyclopeptides (tetramers)
possessing a β-turn [16].
Small molecule with anti-TNFα activity with compact 3D conformations containing
trifluoromethylphenyl indole and chromone moieties have previously been designed. These
compounds bind with high affinity (IC50 = 13 µM) to a hydrophobic binding pocket formed by
six tyrosine residues (Y59, Y119 and Y151 from chain A and B) at the interface of TNFα dimer [17].
Alternative binding pockets that bind small molecules have also been identified from the predicted
TNFα-TNFR1 complex and these involve the residues H66, L67 and L71 of TNFR1 and residues R82,
F90 and F127 in TNFα [18]. Recently, a small molecule benzimidazole derivative (UCB-6876) has
been discovered, a co-crystal structure of UCB-6876 with TNFα resulted in a change in the spatial
arrangement of the TNFα trimer and a loss of its 3-fold symmetry. This compound was also found to
occupy the centre of the TNFα trimer filling a hydrophobic binding pocket involving chain A (Y59),
chain B (L57, Y119) and chain C (Y59, Y151) [19].
2. Results and Discussion
In an attempt to discover improved anti-TNFα therapeutics, we designed a cyclic peptide that
could directly inhibit the TNFα-TNFR1 interaction and have potentially fewer side effects than the small
molecule inhibitors and biologics mentioned above. This was achieved by producing a cyclic peptide
with higher target specificity compared to small molecules and low potential of immunogenicity
when compared with biologics. Protein loops are often involved in the biomolecular recognition of
proteins [20]. Loop peptidomimetics have previously been introduced as a new class of bioactive
agents. The cyclic peptide cyclo-GCRLYGFKIHGCG derived from the regulatory subunit (CK2β) of
protein kinase 2 which inhibits the interaction with the associated catalytic subunit and is used for
cancer therapy [21]. Another example is the macrocyclic peptidomimetic MCP-1, which is an inhibitor
of the menin-MLL protein–protein interaction involved in leukemogenesis [22].
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Structure-based design of exocyclic peptidomimetic inhibitors of TNFα prepared by Takasaki and
colleagues provided a good starting point to develop PPI inhibitors [23]. The two TNFR-1 binding
sites (WP8 and WP9) were known from the structural information available for the TNFβ/TNFR-1
complex (Figure 1A) [24]. The importance of the WP5 binding site was inferred from the light chain
sequences of several TNFα neutralising antibodies which have been shown to contribute to TNFR-1
binding. This data was further supported by the structural homology of the modelled light chain
structure (CDR1) of anti-TNFα with the WP5 site [25].Molecules 2020, 25, x FOR PEER REVIEW 4 of 11 
 
 
Figure 1. Modelling of the inhibition of TNFα-TNFR1 interaction. (A) This figure shows the different 
binding sites of TNFR1 based on the available crystal structure of TNFβ/TNFR-1 complex [PDB: 
1TNR]. The TNFβ structure (blue) bound to TNFR-1 (green) with highlighted 3 TNFR1 binding sites, 
WP5 (magenta), WP8 (yellow) and WP9 (red). (B) 3D view of TNFα homo-trimer (PDB: 1TNF) 
showing residues N92, S99, K112 and E116 (magenta) at the interface that are important for the 
formation of the TNFα bioactive complex. The lowest energy NMR structures of 1 are clustered into 
two main groups, a major group of seven structures, in which (C) is the lowest energy conformation 
and a minor group of three structures in which (D) is the lowest conformation in the cluster. (E) 
illustrates structural similarity between different structures of 1 and WP9 domain. Aligned and 
superimposed docking poses and NMR structures of 1 against the WP9 loop of TNFR-1 are shown in 
red to illustrate their structural similarity. Docking pose 6 is shown in purple, and major and minor 
NMR structures are coloured in yellow and green, respectively. (F) WP9 loop peptidomimetic 1 
docked to TNFα (PDB: 1TNF). The interaction involves four hydrogen bonds with N137, N92 and T79 
residues of TNFα; details can be found in Table S1. 
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binding sites of TNFR1 based on the avail ble crystal struct re of TNFβ/TNFR-1 comple :
1TNR]. The TNFβ structure (blu ) ound to TNFR-1 (green) with highlighted 3 TNFR1 bin i ,
WP5 (magenta), WP8 (yellow) and WP9 (red). (B) 3D view of TNFα homo-trimer (PDB: 1TNF) showing
residues N92, S99, K112 and E116 (magenta) at the interface that are important for the formation of the
TNFα bioactive complex. The lowest energy NMR structures of 1 are clustered into two main groups,
a major group of seven structures, in which (C) is the lowest energy conformation and a minor group
of three structures in which (D) is the lowest conformation in the cluster. (E) illustrates structural
similarity between different structures of 1 and WP9 domain. Aligned and superimposed docking
poses and NMR structures of 1 against the WP9 loop of TNFR-1 are shown in red to illustrate their
structural similarity. Docking pose 6 is shown in purple, and major and minor NMR structures are
coloured in yellow and green, respectively. (F) WP9 loop peptidomimetic 1 docked to TNFα (PDB:
1TNF). The interaction involves four hydrogen bonds with N137, N92 and T79 residues of TNFα; details
can be found in Table S1.
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The design of a new anti-TNFα cyclic peptide 1 (Figure 2) was achieved by extending the 5 residues
(WSENL) of the WP9 loop used to design WP9QY (Figure 2) to the 9 residues [105 HYWSENLFQ
113] which were cyclised head to tail via a proline-glycine linker to help stabilise the loop structure
in an 11mer cyclic peptide; shown in (Table 1). This cyclic peptide showed enhanced binding to
TNFα evaluated by molecular docking (Table S1). The anti-TNFα activity of this new macrocyclic
peptidomimetic of the WP9 binding site 1 in comparison with the known peptide WP9QY (purchased
from Almac, Craigavon, UK) was determined by an in vitro cell-based assay [26]. The corresponding
linear peptide of 1 was not evaluated because of the potential for off target binding due to the high
conformational flexibility of linear peptides.Molecules 2020, 25, x FOR PEER REVIEW 5 of 11 
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of TNFα. 
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TNFα activity of suramin, a polysulphonated naphthylurea which has been used previously to treat 
trypanosomiasis and onchocerciasis. Deoligomerisation of TNFα by suramin was shown by 
measuring the cell-bound radioactivity of cultured K562 cells incubated with 125I-labelled TNFα in 
the presence or absence of suramin [28]. Modelling of a suramin structural analogue bound to TNFα 
has led to prediction of the residues involved in the interaction. These include K112 and E116 which 
have been shown to interact with 1 as well as other residues including T72, K98 and R103 [29]. 
The synthesis of 1 was performed using a Fmoc-based SPPS protocol with a cyclisation yield of 
33.1% at 98.4% purity. The chemical structure of 1 was confirmed by MS/MS and 2D NMR 
experiments (Supplementary Material). NMR experiments were carried out in methanol-d3 due to the 
low solubility of 1 in water. The three-dimensional NMR structure of 1 was determined by NOE-
restrained molecular dynamics (27 NOE restraints) in which the lowest energy structures were found 
to be clustered into two groups (A and B) with 7 converged structures in the main group (A) and 3 
in a minor group (B). The RMSD of the aligned backbones of the best structure in each group was 
3.05 Å. The data showing detailed chemical analysis can be found in the supplementary material. The 
lowest energy NMR structure in each cluster are shown in (Figure 1C,D). 
A molecular similarity study of WP9 loop of TNFR-1 with NMR structures and docking poses 
of 1 was performed by alignment and superimposition of backbone atoms (Table 2, Figure 1E). The 
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can be seen from the low RMSD value (backbone) of 2.09 Å observed. This might suggest a 
mechanism of inhibition for 1 in which 1 binds to nearby residues in the WP9 binding site of TNFα 
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Table 1. Sequence comparison of original WP9 loop and anti-TNFα peptidomimetics.
Peptidomimetics Sequence
Original WP9 Loop HYWSENLFQ
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A Monte Carlo search of the conformational space of 1 was performed to provide candidate
structures for subsequent protein–ligand docking so as to avoid the docking procedure being biased
by a single low-energy input structure. The structures obtained in this way were then docked to TNFα
resulting in docking scores of around −5 kcal/mol as shown in the Supplementary Material, Table
S1. Docking results showed that 1 interacts mainly with four residues of TNFα, namely N92, S99,
K112 and E116, in the WP9 site. These residues were found to also mediate the interaction at the
interface between TNFα monomers during the spontaneous polymerisation as observed in the crystal
structure PDB: 1TNF (Figure 1B) [27]. Consequently, this might suggest an additional mechanism of
TNFα inhibition by 1 which occurs by disrupting the formation of the biologically active homo-trimer
of TNFα.
The homo-multimerisation mechanism was first shown to be biologically relevant to the anti-TNFα
activity of suramin, a polysulphonated naphthylurea which has been used previously to treat
trypanosomiasis and onchocerciasis. Deoligomerisation of TNFα by suramin was shown by measuring
Molecules 2020, 25, 922 5 of 11
the cell-bound radioactivity of cultured K562 cells incubated with 125I-labelled TNFα in the presence
or absence of suramin [28]. Modelling of a suramin structural analogue bound to TNFα has led to
prediction of the residues involved in the interaction. These include K112 and E116 which have been
shown to interact with 1 as well as other residues including T72, K98 and R103 [29].
The synthesis of 1 was performed using a Fmoc-based SPPS protocol with a cyclisation yield of
33.1% at 98.4% purity. The chemical structure of 1 was confirmed by MS/MS and 2D NMR experiments
(Supplementary Materials). NMR experiments were carried out in methanol-d3 due to the low solubility
of 1 in water. The three-dimensional NMR structure of 1 was determined by NOE-restrained molecular
dynamics (27 NOE restraints) in which the lowest energy structures were found to be clustered into
two groups (A and B) with 7 converged structures in the main group (A) and 3 in a minor group (B).
The RMSD of the aligned backbones of the best structure in each group was 3.05 Å. The data showing
detailed chemical analysis can be found in the Supplementary Materials. The lowest energy NMR
structure in each cluster are shown in (Figure 1C,D).
A molecular similarity study of WP9 loop of TNFR-1 with NMR structures and docking poses of 1
was performed by alignment and superimposition of backbone atoms (Table 2, Figure 1E). The structural
resemblance observed between the WP9 loop and the best docking pose (conformation 6) can be
seen from the low RMSD value (backbone) of 2.09 Å observed. This might suggest a mechanism of
inhibition for 1 in which 1 binds to nearby residues in the WP9 binding site of TNFα and abolish the
TNFR-1 interaction (Figure 1F). Furthermore, the lowest energy NMR structure of the main cluster
(structure A) adopts a similar conformation to the WP9 loop of TNFR-1 (RMSD = 2.68) and again
suggesting an analogous binding mode to WP9QY. However, the polarity of the solvent used for NMR
could also contribute to the observed difference in conformation [30].
Table 2. RMSDs for aligned and superimposed docking poses and NMR structures of 1 with reference
to WP9 loop.
Structure RMSD (Å)
(Main Chain)
WP9 domain of TNFR-1 Reference
Docking pose 6 2.09
Docking pose 5 2.27
Docking pose 2 2.44
NMR structure A 2.68
Docking pose 4 2.71
Docking pose 3 2.88
NMR structure B 3.50
Docking pose 1 4.10
A biological assay using a TNFα sensor cell (HEK-Blue TNFα cells, InvivoGen, Toulouse, France)
was used to evaluate the anti-TNFα activity of 1. In the assay, the cells are transfected with a secretory
alkaline phosphatase reporter gene which is downstream of the NF-kB promoter and expressed in
response to TNFα receptor activation. The alkaline phosphatase activity was then quantified by
measuring the absorbance (λ = 620 nm) of coloured substrate. For each assay, approximately 5 × 104
cells were seeded in each well of a 96 well flat-bottomed cell culture plate and incubated for 24 h with
1 ng/mL of recombinant human TNFα and different concentrations of both 1 and WP9QY in duplicates.
Activation of HEK-Blue TNFα cells by 1 ng/mL of human TNFα (InvivoGen) in the presence and
absence of anti-hTNFα antibody (InvivoGen) were used as positive and negative controls in the
anti-TNFα assay (Figure 3). This assay was used as a direct measure of TNFα inhibition effect on cells,
while the affinity of TNFα binding was evaluated by molecular docking results.
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A dose-response curve for TNFα inhibition by both 1 and WP9QY was generated by normalising 
the absorbance readings at 620 nm against dose to percentage. This resulted in IC50 of 133.7 μM (by 
extrapolation) and of 121.7 μM for 1 and WP9QY, respectively (Figure 4). In this assay, the inhibition 
of TNFα activity by 35% is achieved by 117.4 μM and 97.2 μM for 1 and WP9QY respectively. This 
result contrasts with those of Takasaki and co-workers, where the same level of TNFα inhibition was 
Figure 3. Controls used in TNFα assay as a measure of HEK-Blue cells response to TNFα.
Negative control response to TNFα was used to normalise inhibitors’ response to inhibition (%).
Anti-hTNFα antibody was used as positive control with significant difference in response following T
test (P < 0.0001). Error bars are not visible due to the small size of the calculated standard errors.
A dose-response curve for TNFα inhibition by both 1 and WP9QY was generated by normalising
the absorbance readings at 620 nm against dose to percentage. This resulted in IC50 of 133.7 µM (by
extrapolation) and of 121.7 µM for 1 and WP9QY, respectively (Figure 4). In this assay, the inhibition of
TNFα activity by 35% is achieved by 117.4 µM and 97.2 µM for 1 and WP9QY respectively. This result
contrasts with those of Takasaki and co-workers, where the same level of TNFα inhibition was reached
by approximately 2.5 µM of WP9QY when tested by using U937 cells in a flow cytometric assay [23].
Their flow cytometric assay measures anti-TNFα activity as was determined by inhibition of anti-TNF
receptor antibody binding. Bound anti-TNF receptor antibody was then measured by its binding to
fluorescein-labelled secondary antibody which does not represent direct interaction between TNFα
and its receptor, whereas the assay used here quantifies TNFα response directly.
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Figure 4. Dose-response curve of anti-TNFα activities of 1 and WP9QY. This assay was performed with
one duplicate, and the error bar represent standard error. Non-linear regression was used to fit the
curve to the measured data points. While measurements for 1 are well-fit, the WP9QY data shows
slight deviations from those expected, this may be due to a different mode of action.
The assay used in this study is considered more specific for TNFα and measures TNFα activity
directly and therefore provides more accurate results. Furthermore, the use of reporter gene inducible
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by TNFα gives more evidence as to whether the peptide binding would have agonistic or antagonistic
effects downstream of the TNFα signalling pathway. Peptides were dissolved in DMSO and solutions
were diluted with the cell culture media so the final concentration of DMSO is 1%. Blank experiments
with 1% DMSO were carried out. The difference in IC50 between 1 and WP9QY reported here could
also be attributed to a different mode of action of 1 such as deoligomerisation of TNFα homo-trimer by
1 in which the binding to TNFα take place in 1:3 ratio with WP9QY binding stoichiometrically to block
TNFR-1 interaction of the oligomer. This alternative mode of action (deoligmerisation) was proposed
based on our docking results (Table S1), which shows the interaction of 1 with TNFα residues N92, S99,
K112 and E116. These are key residues mediating interfacial interaction between TNFα monomers to
form the biologically active trimer as illustrated in Figure 1B.
An MTT assay (Figure 5) showed no significant cytotoxicity to HEK-Blue TNFα cells at the
concentration used to test anti-TNFα activity of both 1 and WP9QY. Therefore, this can be used as
preliminary data for further biological evaluations.Molecules 2020, 25, x FOR PEER REVIEW 8 of 11 
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Figure 5. MTT assay of HEK-Blue TNFα cells in the presence of 1 and WP9QY. Optical density (OD)
readings at 540 nm correspond to formazan levels formed by viable cells after incubation with 1 and
WP9QY for 24 h. This assay was performed with one duplicate, and the error bars show standard error.
3. Materials and Methods
Fmoc amino acid derivatives, coupling reagents (HBTU, HATU and HOBt), preloaded chlorotrityl
resin (H-Gly 2-ClTrt), sym-collidine, trifluoroacetic acid (TFA), dichloromethane (DCM) and acetonitrile
(HPLC grade) were purchased from Merck (Feltham, UK). N,N-dimethylformamide (DMF), piperidine,
1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP), N,N-diisopropylethylamine (DIEA) and triisopropylsilane
(TIS) were supplied by Alfa Aesar (Lancashire, UK).
A conformational search for thermally accessible structures of 1 was done using the Tinker
molecular modelling package [31]. A set of initial cyclic peptide structures for use in the following
protein-ligand docking studies was generated by Tinker’s monte Monte-Carlo program using the
AMBER99 force field. 5000 steps of Cartesian moves and maximum atom displacement of 3 Å (default)
was used. The temperature was set to 500 K and a maximum RMS gradient for truncated Newton
minimisation of 0.01 (default) used. Final potential energies for each optimised conformation was then
calculated in kcal/mol using Tinker’s analyze executable. The Boltzmann distribution of conformational
ensemble obtained in this way was determined by calculating the Boltzmann factor for each structure
by the following equation:
BF = exp
(
− E
RT
)
(1)
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where BF is the Boltzmann factor, E is the total potential energy in kJ/mol, R is the gas constant
(8.314 J/K/mol), and T is the temperature in kelvin. The ratios of Boltzmann factors for all selected
conformations relative to the highest energy conformation were then calculated. Structural comparison
by molecular overlay (all atoms) for the resulting conformations was carried out by determining root
mean square deviations (RMSDs) in Angstroms for each structure with reference to the lowest energy
conformation. This was done in Discovery Studio Visualizer and all conformations of 1 were docked
to TNFα using AutoDock Vina.
Side chain-protected linear peptide sequence of 1 was synthesised manually using solid phase
peptide synthesis strategy (SPPS). H-Gly 2-ClTrt resin (loading of 1.1 mmol/g and 0.3 g) was first
swelled in DMF for 20 min, and the construction of the peptide sequence was done through cycles
of Fmoc deprotection of attached amino acids and HBTU coupling of the next amino acid in the
sequence. Fmoc deprotection was carried out using 20% piperidine while coupling was done by
mixing molar ratio of amino acid:HBTU:HOBt:DIEA:preloaded resin of 3:3:3:6:1 rotated for 1 h at room
temperature. Reaction progress was monitored by LC-MS. Completed linear peptide sequence was
cleaved from the solid support with 20% HFIP in DCM, dried under vacuum and used for cyclisation
reactions. Macrocyclisation of synthesised linear peptide was carried in DMF under dilution condition
(0.1 mM) using 1.5 equivalents of HATU, HOBt and sym-collidine slowly added to vigorously stirred
peptide solution at room temperature for 24 h. Crude reaction product was then dried and deprotected
using a mixture of 95% TFA, 2.5% TIS and 2.5% water [32]. Product obtained was then purified by
reverse-phase HPLC with 5% to 100% gradient of acetonitrile/water on C-18 column (ACE, HiChrom,
250 mm × 10 mm i.d) followed by lyophilisation. Purified cyclic peptide was then analysed by HPLC,
LC-MS and 2D NMR experiments.
Three-dimensional NMR structure of 1 was calculated in methanol-d3 solution using
NOE-restrained molecular dynamics. The experimental NOE restraint values were directly used in
calculation rather than distances. Here we used NOE restraints calculated from NOESY cross-peak
volume with reference to known distances in the molecule. Cross-peak volumes were calculated using
MestReNova software and NOE restraints by the following equation:
ri j = rre f
(
αre f
αi j
) 1
6
(2)
where, rij and αij are distance and peak volume demanded respectively, and rref and αref represent
distance and peak volume of reference, respectively. The structure calculations were carried out using
XPLOR-NIH by first generating random structures of the cyclic peptide. Then, simulated annealing
was performed by heating the molecules to 3500 K and slowly cooled down to 100 K through 60,000
cooling steps. During simulated annealing, the NOE restraints were used to drive the conformational
ensemble of cyclic peptides. The trans configuration of residue P9 was also taken into consideration
during the calculations. This was determined by a low 13C chemical shift difference of 4.27 ppm
between Cβ and Cγ [30].
TNFα sensor cells (HEK-Blue) were grown in Dulbecco’s Modified Eagle’s medium (DMEM)
containing 4.5 g/L glucose and supplemented with 10% [v/v] heat-inactivated foetal bovine serum, 2 mM
L-glutamine, 100 µg/mL normocin, 50 U/mL penicillin and 50 µg/mL streptomycin. Selective antibiotics
added to the culture medium include 100 µg/mL zeocin and 1 µg/mL puromycin and avoided in initial
cultures (first 2 passages). Maintenance cultures were kept in T-75 cell culture flasks and incubated in
humidified incubator with 5% [v/v] CO2 at 37 ◦C. HEK-Blue cultures reaching 70%–80% confluency
were passaged by first washing and detaching the cells gently with Dulbecco’s phosphate buffered
saline. Cells were then pelleted by centrifugation at 1200 rpm for 5 min. Supernatant was discarded
and cell pellets resuspended in fresh media and used in different assays.
The Vybrant®® MTT assay (Thermo Fisher Scientific) was performed following the manufacturer
protocol. In this assay, cell permeable tetrazolium dye (yellow) was oxidised by mitochondrial oxidases
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in viable cells to yield the water-insoluble formazan (purple) after incubation with HEK-TNFα cells.
Formazan was then solubilised and quantified by measuring the UV absorbance at 540 nm.
4. Conclusions
The rational design strategy used in this study led to the discovery of a new moderate inhibitor
of TNFα-TNFR-1 interaction. This cyclic peptide will be used at starting point for the development
of more effective. The modelling steps, as well as the study of NMR solution structure, helped in
suggesting a mode of action for 1 by correlating the structural similarity between 1 and the WP9 loop
in TNFR-1. The N- to C- macrocyclic structure of 1 may be expected to confer better chemical stability
and bioactivity compared to the disulphide bridged peptidomimetic (WP9QY).
Supplementary Materials: The following are available online, containing data for molecular modelling, LC-MS
and NMR analyses and further details about of TNFα sensor cells.
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